In this podcast, UROONCO RCC chief editor Dr. Carmen Mir interviews Prof. Nizar Tannir from the University of Texas, MD Anderson Cancer Center, USA, on the long-term follow-up data from the phase 3 CheckMate 214 trial: Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC).
 
Prof. Tannir summarises the history and stability of the Checkmate 214 trial results over the last 8 years, before discussing the latest data from his presentation at ASCO GU24 in San Francisco.

For more details on this trail, you can read the abstract on the UROONCO Kidney Cancer  educational platform.